HC Wainwright reissued their buy rating on shares of BioCardia ( NASDAQ:BCDA – Free Report ) in a research report released on Wednesday morning, Benzinga reports. The firm currently has a $25.00 target price on the stock.
BioCardia Price Performance Shares of BCDA opened at $1.97 on Wednesday. The stock has a 50-day moving average of $2.
30 and a 200-day moving average of $2.76. BioCardia has a one year low of $1.
63 and a one year high of $10.79. The company has a market cap of $9.
02 million, a PE ratio of -0.47 and a beta of 1.25.
BioCardia Company Profile ( Get Free Report ) Further Reading Five stocks we like better than BioCardia 3 REITs to Buy and Hold for the Long Term Opal Fuels CEO on Steering the Future of Renewable Natural Gas Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win Manufacturing Stocks Investing 2 Underrated Quantum Computing Companies Starting to Rally Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter ..
Business
BioCardia’s (BCDA) “Buy” Rating Reiterated at HC Wainwright
HC Wainwright reissued their buy rating on shares of BioCardia (NASDAQ:BCDA – Free Report) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $25.00 target price on the stock. BioCardia Price Performance Shares of BCDA opened at $1.97 on Wednesday. The stock has a 50-day moving average of $2.30 and [...]